ANALISIS BEBAN BIAYA DAN KESESUAIAN TARIF PAKET PEMBIAYAAN KESEHATAN PADA PASIEN GAGAL JANTUNG RAWAT INAP
DOI:
https://doi.org/10.36423/pharmacoscript.v9i2.2929Keywords:
Cost of Illness, Gagal Jantung, INA-CBGs, Rawat Inap, FarmakoekonomiAbstract
Gagal jantung merupakan penyakit kardiovaskular dengan beban pembiayaan besar, terutama pada rawat inap. Penelitian kuantitatif non-eksperimental ini menganalisis Cost of Illness (COI) pasien gagal jantung rawat inap periode Januari-Desember 2024 dari perspektif rumah sakit, menilai kesesuaian tarif klaim INA-CBGs terhadap tarif rumah sakit, serta pengaruh karakteristik pasien terhadap besaran biaya. Menggunakan pendekatan prevalence-based dengan desain retrospektif dan total sampling (n=70), data dianalisis dengan membandingkan tarif rumah sakit dengan tarif INA-CBGs kemudian dihitung selisih positif atau negatifnya. Total biaya pengobatan selama periode penelitian mencapai Rp616.674.211 (rerata Rp8.809.632/pasien), didominasi biaya rawat inap (44,43%), obat (17,62%), dan laboratorium (16,82%). Tarif riil rata-rata (Rp7.310.686) signifikan lebih tinggi dari tarif INA-CBGs (Rp6.002.398) (p<0,001); 31 dari 40 kombinasi kode-kelas (77,5%) mengalami selisih negatif, terbesar pada kode gagal jantung dengan tingkat keparahan sedang di kelas 3 (I-4-12-II) dan kode kateterisasi jantung (I-1-15-II). Kelas perawatan (p=0,041) dan jumlah komorbid (p<0,001) berpengaruh signifikan terhadap tarif riil, sedangkan jenis kelamin, usia, dan jenis komorbid tidak berpengaruh. Temuan ini mengindikasikan potensi defisit pembiayaan rumah sakit dan perlunya peninjauan tarif INA-CBGs, khususnya untuk penyakit kardiovaskular dan gagal jantung dengan komorbid, serta strategi pengendalian mutu dan biaya obat.
References
Arisandi, J., Lorensia, A., & Rahem, A. (2025). Determinants of cost discrepancies in inpatients with acute decompensated heart failure. Heart Science Journal. https://doi.org/10.21776/ub.hsj.2025.006.01.13
Cavusoglu, Y., Murat, S., Sahin, A., Colluoglu, I. T., & Ural, D. (2024). Burden of comorbidities in heart failure patients in Türkiye. Turkish Journal of Medical Sciences, 54(7). https://doi.org/https://doi.org/10.55730/1300-0144.5934
Chan, J. C. H., & Chan, M. C. Y. (2023). SGLT2 Inhibitors : The Next Blockbuster Multifaceted Drug ? Medicina, 59(388), 1–13. https://doi.org/https://doi.org/10.3390/medicina59020388
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Skarayadi Oskar, Ramdani Robby, Senja Amergo Tantang, Afifah Fauziah Nurul

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication, with the work [SPECIFY PERIOD OF TIME] after publication simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).





